|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/17/2009 9:07:45 AM
CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.
|
|
|
|
|
|
|
|
|
|
|